CORE IR announces the expansion of its Healthcare Communications and Investor Relations Practice, significantly enhancing the company's ability to provide best-in-class strategic counsel to publicly traded and private healthcare companies.
Read more: https://t.co/hzCPgysB87
Kind of remarkable that a Raleigh bank now owns SVB.
For years, it was impossible to get a direct flight between RDU and SFO -- and Raleigh-area founders complained that it hurt their ability to get VC funding.
This... Most investors really want to see the data and internalize it for themselves. Don't expect a claim about results generated to move anyone until they've looked at the data themselves. Don't forget the deets: model system, design, # animals, error bars, p val's, controls.
The SEC is proud to celebrate #Juneteenth & commemorate the emancipation of all Americans.
Juneteenth is an important time to reflect on the legacy of slavery & how we all have a part in building a more perfect union.
An occasional criticism of exec’s coming out of pitches: “they were defensive”. What does this mean and how do teams avoid it? Being “defensive” usually refers to someone responding angrily to a particular question or comment. Sometimes it also means deflecting the...1/13
In biopharma company pitches, I recommend that you highlight the management team toward the beginning, a few slides in. First, it is how most biopharma companies structure their pitches; investors employ heuristics (sometimes subconsciously) to decide which teams are “in...1/6
Missed this news back in February
SEC proposed modernizing 13G and 13D reporting rules
Most dramatic change would be the timeframe for amending 13G’s. Would cut it down to 5 days across for all institutions 👀
Good chart: https://t.co/T7lviMYB8r
https://t.co/aJXvUbrnYe
Here’s a learning experience thing that I think our communications and IR friends in biotech could benefit from hearing. Maybe it’s something that sounds small but can be viewed externally as not. (1/5)
2021 biotech IPOs via Richard Page at Sumitomo Mitsui. Out of 129 IPOs, 13 are currently trading up, all others are down. Mean return from IPO -(46.5%).
MEMBER NEWS: Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1. KBI to produce material for use in future expected Phase 2 clinical trial of Oragenics' intranasal vaccine candidate. https://t.co/SRsLIoiZEz
Streamline your investor communications with our easy-to-use board meeting minutes template. You can use this comprehensive and downloadable document as is to quickly record and share noteworthy updates, agenda topics, and action items with stakeholders. https://t.co/G4Mzrjx1Bt